Ochsner Cancer Institute, New Orleans, Louisiana.
Ochsner Medical Center, New Orleans, Louisiana.
Cancer. 2021 Jan 15;127(2):266-274. doi: 10.1002/cncr.33243. Epub 2020 Oct 28.
This is the largest and only multivariate study evaluating the difference in mortality from coronavirus disease 2019 (COVID-19) between patients with cancer and patients without cancer in the United States. The objective was to assess COVID-19 mortality rates in patients with cancer versus patients without cancer and uncover possible statistically significant characteristics contributing to mortality.
This retrospective study analyzed patients with cancer and patients without cancer who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from March 1 through April 30, 2020. This was a multicenter study in the state of Louisiana throughout the Ochsner Health System in both tertiary and nontertiary centers. Patients older than 18 years were eligible. Three hundred twelve patients with cancer were compared with 4833 patients without cancer.
Mortality was found to be higher in the cancer group. Patients of advanced age with cancer had a significant increase in mortality (odds ratio [OR], 5.96; P < .001). Other significant risk factors for increased mortality were male sex (OR, 2.15), a history of chronic kidney disease (OR, 3.84), and obesity (OR, 1.30). In hospitalized patients with cancer, adverse vital signs on admission, decreased absolute lymphocyte counts, thrombocytopenia, elevated creatinine, lactic acidosis, and elevated procalcitonin all seemed to increase the risk of death. Among patients with cancer, active or progressive disease (P < .001) and recent therapy (OR, 2.34; 95% confidence interval, 1.08-5.08) were shown to increase mortality.
Patients with cancer have increased mortality in the setting of infection with SARS-CoV-2 in comparison with patients without cancer. Patients with cancer who are 65 years of age or older and those with certain comorbidities have the greatest risk of death. Recent cancer-directed therapy and disease status also seem to play roles in mortality.
This is the largest study of patients with cancer versus patients without cancer to date and is the first multivariate analysis study comparing these 2 patient populations. This study confirms the hypothesis that patients with cancer are at increased risk for mortality and that there are multiple characteristics posing the potential to risk-stratify these patients in the setting of a future outbreak.
这是迄今为止在美国针对癌症患者与非癌症患者因 2019 年冠状病毒病(COVID-19)导致的死亡率差异进行的最大规模且唯一的多变量研究。本研究旨在评估癌症患者 COVID-19 死亡率与非癌症患者的差异,并揭示可能导致死亡率差异的统计学显著特征。
本回顾性研究分析了 2020 年 3 月 1 日至 4 月 30 日期间 SARS-CoV-2 检测呈阳性的癌症患者和非癌症患者。这是路易斯安那州奥克斯纳健康系统内的一项多中心研究,涉及三级和非三级中心。年龄大于 18 岁的患者符合入组条件。将 312 名癌症患者与 4833 名非癌症患者进行比较。
研究发现癌症组死亡率更高。患有癌症的高龄患者死亡率显著增加(优势比[OR],5.96;P <.001)。其他显著增加死亡率的危险因素包括男性(OR,2.15)、慢性肾脏病病史(OR,3.84)和肥胖(OR,1.30)。患有癌症的住院患者中,入院时的不良生命体征、绝对淋巴细胞计数降低、血小板减少、肌酐升高、乳酸酸中毒和降钙素原升高似乎都会增加死亡风险。在癌症患者中,活动期或进展期疾病(P <.001)和近期治疗(OR,2.34;95%置信区间,1.08-5.08)与死亡率增加相关。
与非癌症患者相比,感染 SARS-CoV-2 的癌症患者死亡率更高。65 岁及以上的癌症患者和患有某些合并症的患者死亡风险最大。最近的癌症靶向治疗和疾病状态似乎也会影响死亡率。
这是迄今为止针对癌症患者与非癌症患者的最大规模研究,也是第一项对这两个患者群体进行比较的多变量分析研究。本研究证实了这样一个假设,即癌症患者的死亡风险更高,并且存在多个特征,这些特征可能会在未来的疫情爆发中对这些患者进行风险分层。